Mem Inst Oswaldo Cruz, Rio de Janeiro, VOLUME 115 | JUNE 2020
Original Article

Evaluation of different total Leishmania amazonensis antigens for the development of a first-generation vaccine formulated with a Toll-like receptor-3 agonist to prevent cutaneous leishmaniasis

María José Germanó1,  Esteban Sebastián Lozano1,2, María Victoria Sanchez1, Flavia Alejandra Bruna1, María Fernanda García-Bustos3, Arianna Lourdes Sosa Lochedino1, María Cristina Salomón2, Ana Paula Fernandes4, Juan Pablo Mackern-Oberti1,2, Diego Esteban Cargnelutti1,2,+

1Consejo Nacional de Investigaciones Científicas y Tecnológicas, Universidad Nacional de Cuyo, Instituto de Medicina y Biología Experimental de Cuyo, Mendoza, Argentina
2Universidad Nacional de Cuyo, Facultad de Ciencias Médicas, Mendoza, Argentina
3Consejo Nacional de Investigaciones Científicas y Tecnológicas, Instituto de Patología Experimental, Salta, Argentina
4Universidade Federal de Minas Gerais, Faculdade de Farmácia, Belo Horizonte, MG, Brasil

DOI: 10.1590/0074-02760200067
176 views 16 downloads
ABSTRACT

BACKGROUND Unfortunately, no any vaccine against leishmaniasis has been developed for human use. Therefore, a vaccine based on total Leishmania antigens could be a good and economic approach; and there are different methodologies to obtain these antigens. However, it is unknown whether the method to obtain the antigens affects the integrity and immune response caused by them.
OBJECTIVES to compare the protein profile and immune response generated by total L. amazonensis antigens (TLA) produced by different methods, as well as to analyse the immune response and protection by a first-generation vaccine formulated with sonicated TLA (sTLA) and polyinosinic:polycytidylic acid [Poly (I:C)].
METHODS TLA were obtained by four different methodologies and their integrity and immune response were evaluated. Finally, sTLA was formulated with Poly (I:C) and their protective immune response was measured.
FINDINGS sTLA presented a conserved protein profile and induced a strong immune response. In addition, Poly (I:C) improved the immune response generated by sTLA. Finally, sTLA + Poly (I:C) formulation provided partial protection against L. amazonensis infection.
MAIN CONCLUSIONS The protein profile and immune response depend on the methodology used to obtain the antigens. Also, the formulation sTLA + Poly (I:C) provides partial protection against cutaneous leishmaniasis in mice.

REFERENCES
01. Germano MJ, Salomón MC, Neira G, Lozano E, Mackern-Oberti JP, Cargnelutti DE. Leishmaniasis in Argentine Republic: tTemporal and geographical distribution from 2013 to 2017. Asian Pac J Trop Med. 2019; 12(7): 300-5.
02. Meireles CB, Maia LC, Soares GC, Teodoro IPP, Gadelha M, da Silva CGL, et al. Atypical presentations of cutaneous leishmaniasis: a systematic review. Acta Trop. 2017; 172: 240-54.
03. Silveira FT, Lainson R, Corbett CEP. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil ― A Review. Mem Inst Oswaldo Cruz. 2004; 99(3): 239-51.
04. de Souza CSF, Calabrese KS, Abreu-Silva AL, Carvalho LOP, Cardoso FO, Dorval M, et al. Leishmania amazonensis isolated from human visceral leishmaniasis: histopathological analysis and parasitological burden in different inbred mice. Histol Histopathol. 2018; 33(7): 705-16.
05. Mohebali M, Nadim A, Khamesipour A. An overview of leishmanization experience: a successful control measure and a tool to evaluate candidate vaccines. Acta Trop. 2019; 200: 105173.
06. Sanchez MV, Elicabe RJ, Di Genaro MS, Germano MJ, Gea S, Garcia-Bustos MF, et al. Total Leishmania antigens with Poly(I:C) induce Th1 protective response. Parasite Immunol. 2017; 39(11): 1-5.
07. Salgado CL, Dias EL, Stringari LL, Covre LP, Dietze R, Lima Pereira FE, et al. Pam3CSK4 adjuvant given intranasally boosts anti-Leishmania immunogenicity but not protective immune responses conferred by LaAg vaccine against visceral leishmaniasis. Microbes Infect. 2019; 21(7): 328-35.
08. Alves-Silva MV, Nico D, de Luca PM, Palatnik de-Sousa CB. The F1F3 recombinant chimera of Leishmania donovani-nucleoside hydrolase (NH36) and its epitopes induce cross-protection against Leishmania (V.) braziliensis infection in mice. Front Immunol. 2019; 10: 724.
09. Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG. Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol. 2012; 3: 144.
10. Tahamtan AJ, Shokouh SJH, Barati M. An overview of history, evolution, and manufacturing of various generations of vaccines. J Arch Mil Med. 2017; 5(3): e12315.
11. Nagill R, Mahajan R, Sharma M, Kaur S. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol Int. 2009; 58(4): 359-66.
12. Grenfell RF, Marques-da-Silva EA, Souza-Testasicca MC, Coelho EA, Fernandes AP, Afonso LC, et al. Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production. Mem Inst Oswaldo Cruz. 2010; 105(6): 818-22.
13. Convit J, Ulrich M, Polegre MA, Avila A, Rodríguez N, Mazzedo MI, et al. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin - Preliminary report. Mem Inst Oswaldo Cruz. 2004; 99(1): 57-62.
14. Giunchetti RC, Correa-Oliveira R, Martins-Filho OA, Teixeira- Carvalho A, Roatt BM, Aguiar-Soares RDO, et al. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs. Vaccine. 2007; 25(44): 7674-86.
15. Moafi M, Rezvan H, Sherkat R, Taleban R. Leishmania vaccines entered in clinical trials: a review of literature. Int J Prev Med. 2019; 10: 95.
16. Arjmand R, Fard SS, Saberi S, Tolouei S, Khamesipour A, Hejazi SH. Antigenic profile of heat-killed versus thimerosal-treated Leishmania major using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Adv Biomed Res. 2015; 4: 128.
17. Del Giudice D, Zhou Y, Sinha E, Michalak AM. Long-term phosphorus loading and springtime temperatures explain interannual variability of hypoxia in a large temperate lake. Environ Sci Technol. 2018; 52(4): 2046-54.
18. Martins KA, Bavari S, Salazar AM. Vaccine adjuvant uses of poly-IC and derivatives. Expert Rev Vaccines. 2015; 14(3): 447-59.
19. Cargnelutti DE, Salomon MC, Celedon V, Garcia-Bustos MF, Morea G, Cuello-Carrion FD, et al. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection. J Microbiol Immunol Infect. 2016; 49(1): 24-32.
20. Pirdel L, Farajnia S. A non-pathogenic recombinant Leishmania expressing lipophosphoglycan 3 against experimental infection with Leishmania infantum. Scand J Immunol. 2017; 86(1): 15-22.
21. Germanó MJ, Sanchez MB, Salomón MC, Scodeller EA, Mackern- Oberti JP, Cargnelutti DE. Immune and pathological parameters in balb/c mice infected with different doses of Leishmania (Leishmania) amazonensis. 6th World Congress on Leishmaniasis; 2017 May 16-20; Toledo (Spain).
22. Coelho EA, Tavares CA, Carvalho FA, Chaves KF, Teixeira KN, Rodrigues RC, et al. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun. 2003; 71(7): 3988-94.
23. Brito LA, Singh M. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci. 2011; 100(1): 34-7.
24. Mayrink W, Mendonca-Mendes A, de Paula JC, Siqueira LM, Marrocos SR, Dias ES, et al. Cluster randomised trial to evaluate the effectiveness of a vaccine against cutaneous leishmaniasis in the Caratinga microregion, south-east Brazil. Trans R Soc Trop Med Hyg. 2013; 107(4): 212-9.
25. Gillespie PM, Beaumier CM, Strych U, Hayward T, Hotez PJ, Bottazzi ME. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016; 34(26): 2992-5.
26. Velez R, Gallego M. Commercially approved vaccines for canine leishmaniosis: a review of available data on their safety and efficacy. Trop Med Int Health. 2020; 25(5): 540-57.
27. Lagerqvist N, Naslund J, Lundkvist A, Bouloy M, Ahlm C, Bucht G. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J. 2009; 6: 6.
28. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol. 1999; 163(8): 4481-8.
29. de Matos Guedes HL, Pinheiro RO, Chaves SP, De-Simone SG, Rossi-Bergmann B. Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine. Vaccine. 2010; 28(33): 5491-6.
30. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology 8th ed. Philadelphia: Saunders; 2014. 608 pp.
31. Firmino-Cruz L, Ramos TD, da Fonseca-Martins AM, Maciel- Oliveira D, Oliveira-Silva G, Pratti JES, et al. Immunomodulating role of IL-10-producing B cells in Leishmania amazonensis infection. Cell Immunol. 2018; 334: 20-30.
32. Fechio CJ, Soares AM, de Oliveira SL, Sartori A. Experimental visceral leishmaniasis in high and low antibody-producer mice (selection IV-A). Rev Soc Bras Med Trop. 1999; 32(3): 229-34.
33. Cargnelutti DE, Salomon MC, Celedon V, Cuello-Carrion FD, Gea S, Di Genaro MS, et al. Impact of tumor necrosis factor receptor p55 deficiency in susceptibility of C57BL/6 mice to infection with Leishmania (Leishmania) amazonensis. J Microbiol Immunol Infect. 2016; 49(2): 271-5.

Financial support: Universidad Nacional de Cuyo (UNCuyo SIIP 06/J499), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) (PIP 11220150100210Co 2015-2017), Agencia Nacional de Promoción Científica y Tecnológica (AGENCIA) (PICT Nº 2018-01511), Universidad del Aconcagua (CIUDA 2017-2019) and Secretaría de Políticas Universitarias (SPU) (VT42-UNCU11839).
+ Corresponding author: diegocargnelutti@hotmail.com
ORCID https://orcid.org/0000-0002-1246-7551
Received 13 February 2020
Accepted 15 June 2020

Our Location

Memórias do Instituto Oswaldo Cruz

Av. Brasil 4365, Castelo Mourisco 
sala 201, Manguinhos, 21040-900 
Rio de Janeiro, RJ, Brazil

Tel.: +55-21-2562-1222

This email address is being protected from spambots. You need JavaScript enabled to view it.

Support Program

ioc

fiocruz governo
faperj cnpq capes